Journament

Keyword Connections - Inhibitors Keywords

Connection Type	Connection
Journals	angewandte chemie (international ed in english) European journal of medicinal chemistry Scientific reports Journal of enzyme inhibition and medicinal chemistry Medicine Work Pesticide biochemistry and physiology journal of biological inorganic chemistry : jbic : a publication of the society of biological inorganic chemistry jbi database of systematic reviews and implementation reports scandinavian journal of work, environment & health
Research Groups	No Research Group Connected
Bibliographies	[1] Metal coordination and peripheral substitution modulate the activity of cyclic tetrapyrroles on αS aggregation: a structural and cell-based study. [2] Drivers and barriers in the practice of health-specific leadership: A qualitative study in healthcare. [3] Synthesis and biological evaluation of 1,3,4-thiadiazole derivatives as type III secretion system inhibitors against Xanthomonas oryzae. [4] Synergistic antifungal interactions of amphotericin B with 4-(5-methyl-1,3,4-thiadiazole-2-yl) benzene-1,3-diol. [5] Novel sulphonamides incorporating triazene moieties show powerful carbonic anhydrase I and II inhibitory properties. [6] The kalimantacin polyketide antibiotics inhibit fatty acid biosynthesis in Staphylococcus aureus by targeting the enoyl-acyl carrier protein binding site of FabI. [7] inhibitors of complement activity in human breast-milk: a proposed hypothesis of their physiological significance [8] what are the benefits in the association of sglt2 inhibitors and other drugs? [9] influence of time on bond characteristics between extruded pvc tube and cast htpb/ipdi rocket propellant [10] natural melanogenesis inhibitors acting through the down-regulation of tyrosinase activity [11] specific role of targeted molecular therapy in treatment of oral squamous cell carcinoma [12] hemophilia inhibitor patients: the use of recombinant factor viia [13] glucocorticoids and polyamine inhibitors synergize to kill human leukemic cem cells [14] detoxification of a lignocellulosic waste from a pulp mill to enhance its fermentation prospects [15] Substrate specificity, heat inactivation and inhibition of polyphenol oxidase from different aubergine cultivars [16] Purine nucleoside phosphorylase inhibitors - an immunotherapy with novel mechanism of action for the treatment of melanoma [17] The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer. [18] Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials [19] Cholinesterase inhibitors for Alzheimer's disease [20] Chalcones as potent tyrosinase inhibitors: the importance of a 2, 4-substituted resorcinol moiety [21] New piperidine-hydrazone derivatives: Synthesis, biological evaluations and molecular docking studies as AChE and BChE inhibitors [22] Sulfonamide derivatives as inhibitors: in silico approach. [23] Design, synthesis, and biological evaluation of selective and potent Carbazole-based butyrylcholinesterase inhibitors. [24] Sulfonamido-derivatives of unsubstituted carbazoles as BACE1 inhibitors. [25] Discovery of tetrahydrocarbazoles as dual pERK and pRb inhibitors. [26] Synthesis, evaluation and molecular modelling studies of 2-(carbazol-3-yl)-2-oxoacetamide analogues as a new class of potential pancreatic lipase inhibitors. [27] Novel 1,5-Diphenylpyrazole Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors with Enhanced Activity versus the Delavirdine-Resistant P236L Mutant: Lead Identification and SAR of 3- and 4-Substituted Derivatives [28] Pharmacophores modeling in terms of prediction of theoretical physico-chemical properties and verification by experimental correlations of Carbacylamidophosphates (CAPh) and Sulfanylamidophosphates (SAPh) Tested as New Carbonic Anhydrase Inhibitors. [29] Cyrmenins, new beta-methoxyacrylate inhibitors of the electron transport. Production, isolation, physico-chemical and biological properties. [30] EI-1941-1 and -2, novel interleukin-1 beta converting enzyme inhibitors Produced by Farrowia sp. E-1941. II. Taxonomy of producing strain, fermentation, isolation, physico-chemical properties, and biological properties. [31] Convenient framework of poly functionalized (E)-2-benzylideno-(Z)-carbazolylideno cyanoacetamides via rearrangements as an efficient antibiofilm inhibitors with SAR study. [32] Cholinesterase inhibitors as Alzheimer's therapeutics (Review). [33] Synthesis and biological evaluation of indoloquinoline alkaloid cryptolepine and its bromo-derivative as dual cholinesterase inhibitors. [34] Use of Cholinesterase Inhibitors in Non-Alzheimer's Dementias. [35] Tubes for detection of cholinesterase inhibitors-Unique effects of Neusilin on the stability of butyrylcholinesterase-impregnated carriers. [36] Coumarin derivatives as acetyl- and butyrylcholinestrase inhibitors: An in vitro, molecular docking, and molecular dynamics simulations study. [37] Synthesis, biological evaluation and docking studies of chalcone and flavone analogs as antioxidants and acetylcholinesterase inhibitors [38] Investigation of potent inhibitors of cholinesterase based on thiourea and pyrazoline derivatives: Synthesis, inhibition assay and molecular modeling studies. [39] Design, Synthesis, and Structure-Activity Relationships of 1,2,3-Triazole Benzenesulfonamides as New Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors. [40] Synthesis of a new series of 3-functionalised-1-phenyl-1,2,3-triazole sulfamoylbenzamides as carbonic anhydrase I, II, IV and IX inhibitors. [41] Novel morpholine containing cinnamoyl amides as potent tyrosinase inhibitors. [42] Discovery of tropinone-thiazole derivatives as potent caspase 3/7 activators, and noncompetitive tyrosinase inhibitors with high antiproliferative activity: Rational design, one-pot tricomponent synthesis, and lipophilicity determination. [43] PIM kinase inhibitors: Structural and pharmacological perspectives. [44] Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature. [45] Erratum to "Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac". [46] Synthesis, activity testing and molybdenum(VI) complexation of Schiff bases derived from 2,4,6-trihydroxybenzaldehyde investigated as xanthine oxidase inhibitors. [47] 3,5-Diamino-1,2,4-triazoles as a novel scaffold for potent, reversible LSD1 (KDM1A) inhibitors. [48] Synthesis and anticancer evaluation of novel triazole linked N-(pyrimidin-2-yl)benzo[d]thiazol-2-amine derivatives as inhibitors of cell survival proteins and inducers of apoptosis in MCF-7 breast cancer cells. [49] Discovery and biological evaluation of novel 6,7-disubstituted-4-(2-fluorophenoxy)quinoline derivatives possessing 1,2,3-triazole-4-carboxamide moiety as c-Met kinase inhibitors [50] Pharmacological characterization of the seven human NOX isoforms and their inhibitors. [51] Effects of nitrification inhibitors on gross N nitrification rate, ammonia oxidizers, and NO production under different temperatures in two pasture soils. [52] Co-crystalization and in vitro biological characterization of 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors. [53] Synthesis and evaluation of tetrahydropyrazolopyridine inhibitors of anion exchange protein SLC26A4 (pendrin). [54] Synthesis and Evaluation of Novel Pyrazole Ethandiamide Compounds as Inhibitors of Human THP-1 Monocytic Cell Neurotoxicity. [55] Novel Pyrazoloquinolin-2-ones: Design, synthesis, docking studies, and biological evaluation as antiproliferative EGFR-TK inhibitors. [56] Design, synthesis and anticervical cancer activity of new benzofuran-pyrazol-hydrazono- thiazolidin-4-one hybrids as potential EGFR inhibitors and apoptosis inducing agents. [57] Design, synthesis and biological evaluation of 2-H pyrazole derivatives containing morpholine moieties as highly potent small molecule inhibitors of APC–Asef interaction [58] Synthesis and biological evaluation of purine-pyrazole hybrids incorporating thiazole, thiazolidinone or rhodanine moiety as 15-LOX inhibitors endowed with anticancer and antioxidant potential [59] Recent Developments in Alpha-Glucosidase Inhibitors for Management of Type-2 Diabetes: An Update. [60] Diselenides and Benzisoselenazolones as Antiproliferative Agents and Glutathione-S-Transferase Inhibitors [61] Synthesis, Biological and In Silico Evaluation of Pure Nucleobase-Containing Spiro (Indane-Isoxazolidine) Derivatives as Potential Inhibitors of MDM2–p53 Interaction [62] First-In-Class Inhibitors Targeting the Interaction between Bacterial RNA Polymerase and Sigma Initiation Factor Affect the Viability and Toxin Release of Streptococcus pneumoniae [63] Molecular Docking Study of Four Chromene Derivatives as Novel HIV-1 Integrase Inhibitors [64] Design, synthesis and biological evaluation of 3,4-diaryl-1,2,5-oxadiazole-2/5-oxides as highly potent inhibitors of tubulin polymerization. [65] Synthesis of novel (R)-4-fluorophenyl-1H-1,2,3-triazoles: A new class of α-glucosidase inhibitors. [66] Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group. [67] Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. [68] Triazole derivatives as inhibitors of Alzheimer's disease: Current developments and structure-activity relationships [69] Non-vitamin K antagonist oral anticoagulants with amiodarone, P-glycoprotein inhibitors, or polypharmacy in patients with atrial fibrillation: Systematic review and meta-analysis [70] Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus [71] Approaches to hepatitis C treatment and cure using NS5A inhibitors [72] Influenza treatment and prophylaxis with neuraminidase inhibitors: a review [73] Patterns of resistance development with integrase inhibitors in HIV [74] Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors [75] A review on the diagnosis and treatment of hepatocellular carcinoma with a focus on the role of Wnts and the dickkopf family of Wnt inhibitors [76] P2Y12 inhibitors for acute coronary syndromes: current perspectives [77] Exclusive Cutaneous and Subcutaneous Sarcoidal Granulomatous Inflammation due to Immune Checkpoint Inhibitors: Report of Two Cases with Unusual Manifestations and Review of the Literature [78] Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus [79] Approaches to hepatitis C treatment and cure using NS5A inhibitors [80] Influenza treatment and prophylaxis with neuraminidase inhibitors: a review [81] Patterns of resistance development with integrase inhibitors in HIV [82] Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors [83] A review on the diagnosis and treatment of hepatocellular carcinoma with a focus on the role of Wnts and the dickkopf family of Wnt inhibitors [84] P2Y12 inhibitors for acute coronary syndromes: current perspectives [85] Correction to: Highly Potent 2-Oxoester Inhibitors of Cytosolic Phospholipase A<inf>2</inf> (GIVA cPLA<inf>2</inf>) (ACS Omega (2018) 3:8 (8843?8853) DOI: 10.1021/acsomega.8b01214) [86] Structure-Based Drug Design for Cytochrome P450 Family 1 Inhibitors [87] Dehydroabietylamine Ureas and Thioureas as Tyrosyl-DNA Phosphodiesterase 1 Inhibitors That Enhance the Antitumor Effect of Temozolomide on Glioblastoma Cells. [88] Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. [89] Elucidation of the inhibition mechanism of sulfiredoxin using molecular modeling and development of its inhibitors. [90] The impact of four processing methods on trypsin-, chymotrypsin- and alpha-amylase inhibitors present in underutilised legumes. [91] Safety and efficacy of sodium glucose co-transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials [92] Evidence-based comparison of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors. [93] 4D-QSAR and MIA-QSAR study on the Bruton's tyrosine kinase (Btk) inhibitors. [94] Discovery of novel functionalized 1,2,4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation. [95] Structure Kinetics Relationships and Molecular Dynamics show crucial role for heterocycle leaving group in irreversible diacylglycerol lipase inhibitors. [96] New amide linked dimeric 1,2,3-triazoles bearing aryloxy scaffolds as a potent antiproliferative agents and EGFR tyrosine kinase phosphorylation inhibitors. [97] DFT Study of Azole Corrosion Inhibitors on Cu2O Model of Oxidized Copper Surfaces: I. Molecule–Surface and Cl–Surface Bonding [98] Glycine transporter inhibitors: A new avenue for managing neuropathic pain [99] Adoption of New Glucose-Lowering Medications in the U.S. - the case of SGLT2 inhibitors: Nationwide cohort study. [100] Discovery of Lipid Peroxidation Inhibitors from Species Prioritized through Multivariate Data Analysis and Multi-Informative Molecular Networking. [101] Decreased incidence of Kaposi sarcoma after kidney transplant in Italy and role of mTOR-inhibitors: 1997–2016